CoChat

PSMC5 regulates microglial polarization and activation in LPS-induced cognitive deficits and motor impairments by interacting with TLR4

Open access

Published version of a preprint

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

Abstract

Luteolin is a flavonoid found in high concentrations in celery and green pepper, and acts as a neuroprotectant. PSMC5 (proteasome 26S subunit, ATPase 5) protein levels were reduced after luteolin stimulation in activated microglia. We aimed to determine whether regulating PSMC5 expression could inhibit neuroinflammation, and investigate the underlying mechanisms.BV2 microglia were transfected with siRNA PSMC5 before the addition of LPS (lipopolysaccharide, 1.0 µg/ml) for 24 h in serum free DMEM. A mouse model of LPS-induced cognitive and motor impairment was established to evaluate the neuroprotective effects of shRNA PSMC5. Intracerebroventricular administration of shRNA PSMC5 was commenced 7 days prior to i.p. injection of LPS (750 μg/kg). Treatments and behavioral experiments were performed once daily for 7 consecutive days. Behavioral tests and pathological/biochemical assays were performed to evaluate LPS-induced hippocampal damage. Molecular dynamics simulation was used to confirm the interaction between PSMC5 and TLR4 (Toll-like receptor 4) in LPS-stimulated BV2 microglia. SiRNA PSMC5 inhibited BV2 microglial activation, and suppressed the release of inflammatory factors (IL-1β, COX-2, PGE 2 , TNF-α, and iNOS) upon after LPS stimulation in BV2 microglia. LPS increased IκB-α and p65 phosphorylation, which was attenuated by siRNA PSMC5. Behavioral tests and pathological/biochemical assays showed that shRNA PSMC5 attenuated LPS-induced cognitive and motor impairments, and restored synaptic ultrastructure and protein levels in mice. ShRNA PSMC5 reduced pro-inflammatory cytokine (TNF-α, IL-1β, PGE 2 , and NO) levels in the serum and brain, and relevant protein factors (iNOS and COX-2) in the brain. Furthermore, shRNA PSMC5 upregulated the anti-inflammatory mediators interleukin IL-4 and IL-10 in the serum and brain, and promoted a pro-inflammation-to-anti-inflammation phenotype shift in microglial polarization. Mechanistically, shRNA PSMC5 significantly alleviated LPS-induced TLR4 expression. The polarization of LPS-induced microglial pro-inflammation phenotype was abolished by TLR4 inhibitor and in the TLR-4 −/− mouse, as in shRNA PSMC5 treatment. PSMC5 interacted with TLR4 via the amino sites Glu284, Met139, Leu127, and Phe283. PSMC5 site mutations attenuated neuroinflammation and reduced pro-inflammatory factors by reducing TLR4-related effects, thereby reducing TLR4-mediated MyD88 (myeloid differentiation factor 88)-dependent activation of NF-κB. PSMC5 could be an important therapeutic target for treatment of neurodegenerative diseases involving neuroinflammation-associated cognitive deficits and motor impairments induced by microglial activation. Graphical Abstract

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12974-023-02904-9

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Schematic representation of experimental procedure. I.c.v. shRNA PSMC5 injection was administrated 7 days before LPS injection. Behavioral training tests were delivered to mice at days -7, -5, and -3 respectively. At day 0, behavioral tests were performed
Fig. 1 Schematic representation of experimental procedure. I.c.v. shRNA PSMC5 injection was administrated 7 days before LPS injection. Behavioral training tests were delivered to mice at days -7, -5, and -3 respectively. At day 0, behavioral tests were performedCC BY · PubMed Central
Fig. 2 PSMC5 expression in microglia upon after luteolin treatment. A, B Protein spots identified using 2-DE gels between LPS and luteolin (Lut) treatment groups in BV2 cells, and differences in spot intensity shown by MALDI–TOF-MS to identify PSMC5. C Lut treatment downregulated PSMC5 protein levels in BV2 cells. *p < 0.05 and **p < 0.01 versus the LPS group. D PSMC5 protein levels in mouse brain at different time points in mice treated with LPS. *p < 0.05 and **p < 0.01 versus the control group. E PSMC5 protein levels in the mouse brain after i.c.v. shRNA PSMC5 injection at different times and volumes. F PSMC5 protein levels in the mouse brain after i.c.v. shRNA PSMC5 injection. n = 3–4, data are expressed as means ± SEM, *p < 0.05 and **p < 0.01 versus the control, saline, shRNA PSMC5, and NC groups; #P < 0.05, ##P < 0.01 versus the shRNA PSMC5 + LPS group
Fig. 2 PSMC5 expression in microglia upon after luteolin treatment. A, B Protein spots identified using 2-DE gels between LPS and luteolin (Lut) treatment groups in BV2 cells, and differences in spot intensity shown by MALDI–TOF-MS to identify PSMC5. C Lut treatment downregulated PSMC5 protein levels in BV2 cells. *p < 0.05 and **p < 0.01 versus the LPS group. D PSMC5 protein levels in mouse brain at different time points in mice treated with LPS. *p < 0.05 and **p < 0.01 versus the control group. E PSMC5 protein levels in the mouse brain after i.c.v. shRNA PSMC5 injection at different times and volumes. F PSMC5 protein levels in the mouse brain after i.c.v. shRNA PSMC5 injection. n = 3–4, data are expressed as means ± SEM, *p < 0.05 and **p < 0.01 versus the control, saline, shRNA PSMC5, and NC groups; #P < 0.05, ##P < 0.01 versus the shRNA PSMC5 + LPS groupCC BY · PubMed Central
Fig. 3 ShRNA PSMC5 suppressed neuroinflammation in BV2 cells. A The effect of shRNA PSMC5 on the pro-inflammatory cytokines IL-1α, COX-2, PGE2, and TNF-α in LPS-stimulated BV2 microglia. Q-PCR analysis of IL-1β, COX-2, and TNF-α mRNA expression. ELISA measuring the production of IL-1β, PGE2, and TNF-α. B Effect of shRNA PSMC5 on iNOS and COX-2 levels in BV2 microglia after LPS-induced neuroinflammation. C Signaling components of MyD88-dependent signaling pathway analyzed in BV2 using western blot with the indicated antibodies. D Cellular distribution of NF-κB p65 subunit (Green). Hoechst 33,258 (blue) was used for visualizing nuclei. Scale bar = 100 μm
Fig. 3 ShRNA PSMC5 suppressed neuroinflammation in BV2 cells. A The effect of shRNA PSMC5 on the pro-inflammatory cytokines IL-1α, COX-2, PGE2, and TNF-α in LPS-stimulated BV2 microglia. Q-PCR analysis of IL-1β, COX-2, and TNF-α mRNA expression. ELISA measuring the production of IL-1β, PGE2, and TNF-α. B Effect of shRNA PSMC5 on iNOS and COX-2 levels in BV2 microglia after LPS-induced neuroinflammation. C Signaling components of MyD88-dependent signaling pathway analyzed in BV2 using western blot with the indicated antibodies. D Cellular distribution of NF-κB p65 subunit (Green). Hoechst 33,258 (blue) was used for visualizing nuclei. Scale bar = 100 μmCC BY · PubMed Central
Fig. 4 ShRNA PSMC5 alleviated cognitive impairment and motor disjunction, and improved synaptic structure in LPS-induced mice. A Results of the MWM test for shRNA PSMC5-treated mice, n = 15. B Results of the PAT test for shRNA PSMC5-treated mice, n = 15. C, D Motor coordination scores for shRNA PSMC5-treated mice. C Pole test score, n = 15. D Traction test score, n = 15. Data are presented as mean ± SEM. *P < 0.05, **P < 0.01 compared to the control, saline, shRNA PSMC5, and VIPER groups; #P < 0.05, ##P < 0.01 compared to the shRNA PSMC5 + LPS, VIPER + LPS, and shRNA PSMC5 + VIPER + LPS groups, analyzed by one-way ANOVA. Error bars indicate SEM. E Hematoxylin and eosin staining shows effect of shRNA PSMC5 on hippocampus neurons in LPS-induced mice. Representative photomicrographs of the hippocampus CA3 and CA4 area showing the histological changes of each group. n = 5 mice/group, n = 30 felds/group. F Transmission electron microscopy staining shows effects of shRNA PSMC5 treatment on synapses in the hippocampus. The green arrow shows the synaptic structure. n = 5 mice/group, n = 30 felds/group. G Effect of shRNA PSMC5 treatment on SYP and PSD95 levels in the mice brain. n = 3–4 mice/group
Fig. 4 ShRNA PSMC5 alleviated cognitive impairment and motor disjunction, and improved synaptic structure in LPS-induced mice. A Results of the MWM test for shRNA PSMC5-treated mice, n = 15. B Results of the PAT test for shRNA PSMC5-treated mice, n = 15. C, D Motor coordination scores for shRNA PSMC5-treated mice. C Pole test score, n = 15. D Traction test score, n = 15. Data are presented as mean ± SEM. *P < 0.05, **P < 0.01 compared to the control, saline, shRNA PSMC5, and VIPER groups; #P < 0.05, ##P < 0.01 compared to the shRNA PSMC5 + LPS, VIPER + LPS, and shRNA PSMC5 + VIPER + LPS groups, analyzed by one-way ANOVA. Error bars indicate SEM. E Hematoxylin and eosin staining shows effect of shRNA PSMC5 on hippocampus neurons in LPS-induced mice. Representative photomicrographs of the hippocampus CA3 and CA4 area showing the histological changes of each group. n = 5 mice/group, n = 30 felds/group. F Transmission electron microscopy staining shows effects of shRNA PSMC5 treatment on synapses in the hippocampus. The green arrow shows the synaptic structure. n = 5 mice/group, n = 30 felds/group. G Effect of shRNA PSMC5 treatment on SYP and PSD95 levels in the mice brain. n = 3–4 mice/groupCC BY · PubMed Central
Fig. 5 ShRNA PSMC5 treatment shifted microglial polarization from pro-inflammatory phenotypes toward to anti-inflammatory phenotypes after LPS-induced neuroinflammation. A ShRNA PSMC5 decreased the number of TNF-α-positive microglia (M1) and increased the number of YM-1-positive microglia (M2) in the hippocampus. Representative images of triple-staining immunofluorescence for TNF-α (red), YM-1 (green), and IBA-1 (purple) with DAPI nuclear counterstain in the hippocampus. B ShRNA PSMC5 treatment decreased LPS-induced pro-inflammatory cytokines in the serum and brain. Pro-inflammatory cytokines were detected by ELISA and Griess assay. C ShRNA PSMC5 treatment increased LPS-induced anti-inflammatory cytokine production in the serum and brain. Anti-inflammatory cytokines were detected by ELISA. D Effect of shRNA PSMC5 treatment on iNOS and COX-2 levels in the brain after LPS-induced neuroinflammation. ShRNA PSMC5 treatment alleviated the expression of iNOS and COX-2 protein. n = 3–4 mice/group.Data are presented as mean ± SEM. *P < 0.05, **P < 0.01 compared to the control, saline, shRNA PSMC5, and VIPER groups; #P < 0.05, ##P < 0.01 compared to the shRNA PSMC5 + LPS, VIPER + LPS, and shRNA PSMC5 + VIPER + LPS groups, analyzed by one-way ANOVA. Error bars indicate SEM
Fig. 5 ShRNA PSMC5 treatment shifted microglial polarization from pro-inflammatory phenotypes toward to anti-inflammatory phenotypes after LPS-induced neuroinflammation. A ShRNA PSMC5 decreased the number of TNF-α-positive microglia (M1) and increased the number of YM-1-positive microglia (M2) in the hippocampus. Representative images of triple-staining immunofluorescence for TNF-α (red), YM-1 (green), and IBA-1 (purple) with DAPI nuclear counterstain in the hippocampus. B ShRNA PSMC5 treatment decreased LPS-induced pro-inflammatory cytokines in the serum and brain. Pro-inflammatory cytokines were detected by ELISA and Griess assay. C ShRNA PSMC5 treatment increased LPS-induced anti-inflammatory cytokine production in the serum and brain. Anti-inflammatory cytokines were detected by ELISA. D Effect of shRNA PSMC5 treatment on iNOS and COX-2 levels in the brain after LPS-induced neuroinflammation. ShRNA PSMC5 treatment alleviated the expression of iNOS and COX-2 protein. n = 3–4 mice/group.Data are presented as mean ± SEM. *P < 0.05, **P < 0.01 compared to the control, saline, shRNA PSMC5, and VIPER groups; #P < 0.05, ##P < 0.01 compared to the shRNA PSMC5 + LPS, VIPER + LPS, and shRNA PSMC5 + VIPER + LPS groups, analyzed by one-way ANOVA. Error bars indicate SEMCC BY · PubMed Central
Fig. 6 ShRNA PSMC5 inhibited MyD88-dependent signaling pathway activation and suppressed transition of microglial polarization from M2 to M1 phenotype under neuroinflammatory conditions. Protein expression of signaling components of the MyD88-dependent pathway were analyzed using the indicated antibodies by western blot. n = 3–4 mice/group.Data are presented as mean ± SEM. *P < 0.05, **P < 0.01 compared to the control, saline, shRNA PSMC5, and VIPER groups; #P < 0.05, ##P < 0.01 compared to the shRNA PSMC5 + LPS, VIPER + LPS, and shRNA PSMC5 + VIPER + LPS groups, analyzed by one-way ANOVA. Error bars indicate SEM
Fig. 6 ShRNA PSMC5 inhibited MyD88-dependent signaling pathway activation and suppressed transition of microglial polarization from M2 to M1 phenotype under neuroinflammatory conditions. Protein expression of signaling components of the MyD88-dependent pathway were analyzed using the indicated antibodies by western blot. n = 3–4 mice/group.Data are presented as mean ± SEM. *P < 0.05, **P < 0.01 compared to the control, saline, shRNA PSMC5, and VIPER groups; #P < 0.05, ##P < 0.01 compared to the shRNA PSMC5 + LPS, VIPER + LPS, and shRNA PSMC5 + VIPER + LPS groups, analyzed by one-way ANOVA. Error bars indicate SEMCC BY · PubMed Central
Fig. 7 TLR4 knockout in mice protected against LPS-induced neuroinflammation and cognitive and motor impairments. A–D Morris water maze (MWM), passive avoidance test (PAT), pole test, and traction test were performed to test the memory ability and motor coordination in mice that received the indicated treatments. n = 15. E The expression of the pro-inflammatory cytokines TNF-α, IL-1β, and PGE2 in mouse serum and brain were determined using ELISA kits. F Expression of the anti-inflammatory cytokines IL-4 and IL-10 in mouse serum and brain were studied using ELISA kits. G ShRNA PSMC5 targeted TLR4 to ameliorate LPS-induced neuroinflammation. The expression levels of the signaling components of the TLR4-pathway in mouse hippocampus were determined using western blot with the indicated antibodies. E–G n = 3–4 mice/group,data are presented as mean ± SEM. *P < 0.05, **P < 0.01 compared to control group; #P < 0.05, ##P < 0.01 compared to LPS (TLR4−/−) group, analyzed by one-way ANOVA. Error bars indicate SEM
Fig. 7 TLR4 knockout in mice protected against LPS-induced neuroinflammation and cognitive and motor impairments. A–D Morris water maze (MWM), passive avoidance test (PAT), pole test, and traction test were performed to test the memory ability and motor coordination in mice that received the indicated treatments. n = 15. E The expression of the pro-inflammatory cytokines TNF-α, IL-1β, and PGE2 in mouse serum and brain were determined using ELISA kits. F Expression of the anti-inflammatory cytokines IL-4 and IL-10 in mouse serum and brain were studied using ELISA kits. G ShRNA PSMC5 targeted TLR4 to ameliorate LPS-induced neuroinflammation. The expression levels of the signaling components of the TLR4-pathway in mouse hippocampus were determined using western blot with the indicated antibodies. E–G n = 3–4 mice/group,data are presented as mean ± SEM. *P < 0.05, **P < 0.01 compared to control group; #P < 0.05, ##P < 0.01 compared to LPS (TLR4−/−) group, analyzed by one-way ANOVA. Error bars indicate SEMCC BY · PubMed Central
Fig. 8 PSMC5 interacts with TLR4. A Colocalization of PSMC5 (red) and TLR4 (green), with DAPI nuclear counterstain in the BV2 microglia. Scale bar = 10 µm. B In silico modeling of PSMC5 interactions with TLR4. C Coimmunoprecipitation of endogenous PSMC5 and TLR4 in BV2 cells; precipitation was carried out with TLR4 antibody or IgG followed by WB analysis with antibodies against PSMC5 and TLR4. D GST-pull down to verify the computer molecular docking results. E PSMC5 expression after PSMC5 knockdown in the PSMC5 wild-type and PSMC5 mutants. F Western blot analysis of protein expression of the inflammatory proteins iNOS and COX-2, and MyD88-dependent signaling pathway components in the PSMC5 wild-type and mutants. G Results of the Griess assay showing NO content in the PSMC5 mutants. H ELISA analysis showing the PGE2 content in the PSMC5 mutants
Fig. 8 PSMC5 interacts with TLR4. A Colocalization of PSMC5 (red) and TLR4 (green), with DAPI nuclear counterstain in the BV2 microglia. Scale bar = 10 µm. B In silico modeling of PSMC5 interactions with TLR4. C Coimmunoprecipitation of endogenous PSMC5 and TLR4 in BV2 cells; precipitation was carried out with TLR4 antibody or IgG followed by WB analysis with antibodies against PSMC5 and TLR4. D GST-pull down to verify the computer molecular docking results. E PSMC5 expression after PSMC5 knockdown in the PSMC5 wild-type and PSMC5 mutants. F Western blot analysis of protein expression of the inflammatory proteins iNOS and COX-2, and MyD88-dependent signaling pathway components in the PSMC5 wild-type and mutants. G Results of the Griess assay showing NO content in the PSMC5 mutants. H ELISA analysis showing the PGE2 content in the PSMC5 mutantsCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 54 references

Cited by

See all 36

Metadata

Authors
Bi, W., Bao, K., Zhou, X., Deng, Y., Li, X., Zhang, J., Lan, X., Zhao, J., Lu, D., Xu, Y., Cen, Y., Cao, R., Xu, M., Zhong, W., & Zhu, L.
Affiliations
  • University of Jinan (CN)
  • Jinan University (CN)
Corresponding author
Zhu, Lihong
Venue
Journal of Neuroinflammation
Published
2023-11-24
Volume
20
Issue
1
Pages
277-277
ISSN
1742-2094 (ISSN-L)
OpenAlex
W4388971273
Cited by
36
References
54
Citations by year
2026: 5 · 2025: 19 · 2024: 12
FWCI
3.69
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Neuroinflammation (publishedVersion, cc-by)
  • Research Square (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • the Guangdong Basic and Applied Basic Research Foundation (Nos.2022A1515010842)
  • the Science and Technology Program of Guangzhou (Nos.202102010099, Nos. SL2023A03J00699)
  • the Clinical Frontier Technology Program of the First Affiliated Hospital of Jinan University (Nos. JNU1AF-CFTP-2022-a01216)
  • the Natural Science Foundation of China (Nos.82071568)
  • the Administration of Traditional Chinese Medicine of Guangdong Province (Nos.20202041)
  • the Guangzhou Key Laboratory for Germ-free animals and Microbiota Application ((Nos.202201020381))
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
Keywords
microglial polarization, microglial activation, TLR4, lipopolysaccharide, neuroinflammation, cognitive impairment, motor impairment, hippocampal lesions, neuroprotection, luteolin, NF-κB signaling, inflammatory cytokines, synaptic ultrastructure, anti-inflammatory cytokines
MeSH terms
Motor Disorders, ATPases Associated with Diverse Cellular Activities, Neuroinflammatory Diseases, Animals, Cognition, Inflammation, Lipopolysaccharides, Tumor Necrosis Factor-alpha, Signal Transduction, NF-kappa B, Microglia, RNA, Small Interfering, Proteasome Endopeptidase Complex, Luteolin, Toll-Like Receptor 4, Mice, Cyclooxygenase 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PSMC5 regulates microglial polarization and activation in LPS-induced cognitive deficits and motor impairments by interacting with TLR4. https://app.cochat.ai/papers/10.1186/s12974-023-02904-9
The paper
Bi, W., Bao, K., Zhou, X., Deng, Y., Li, X., Zhang, J., Lan, X., Zhao, J., Lu, D., Xu, Y., Cen, Y., Cao, R., Xu, M., Zhong, W., & Zhu, L. (2023). PSMC5 regulates microglial polarization and activation in LPS-induced cognitive deficits and motor impairments by interacting with TLR4. Journal of Neuroinflammation. https://doi.org/10.1186/s12974-023-02904-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.